Home » Advanced Materials » Japan Biomaterials Market

Japan Biomaterials Market

Japan Biomaterials Market By Product Type (Metallic [Stainless Steel, Gold, Magnesium, Silver, Others], Ceramic [Aluminum Oxide, Calcium Sulfate, Carbon, Glass, Others], Polymer [Polymethylmethacrylate, Polyethylene, Polyester, Nylon, Others], Natural [Hyaluronic Acid, Collagen, Gelatin, Fibrin and Others], Others); By Application (Cardiovascular, Orthopedics, Plastic Surgery, Ophthalmology, Dental, Neurology, Tissue Engineering, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Japan Biomaterials Market Size 2024	USD 12,074.40 million
Japan Biomaterials Market, CGR	15.52%
Japan Biomaterials Market Size 2032	USD 38,281.73 million

Market Overview

Japan Biomaterials market size was valued at USD 12,074.40 million in 2024 and is anticipated to reach USD 38,281.73 million by 2032, at a CAGR of 15.52% during the forecast period (2024-2032).

The Japan biomaterials market is driven by several key factors, including the country’s aging population, increasing healthcare demands, and advancements in medical technology. With a growing focus on personalized medicine, the demand for biocompatible materials in implants, prosthetics, and tissue engineering continues to rise. Additionally, Japan’s robust research and development in regenerative medicine and innovative biomaterials are contributing to market growth. The government’s support for healthcare innovation and sustainability also plays a crucial role in accelerating the adoption of eco-friendly biomaterials. Trends such as the integration of nanotechnology and 3D printing in biomaterial development further enhance the efficiency and functionality of medical applications, attracting significant investment. These factors collectively drive the expansion of the biomaterials market, positioning Japan as a leader in the global healthcare materials sector.

Japan’s biomaterials market is geographically diverse, with key regions including Kanto, Kansai, Chubu, and Kyushu, each contributing to the market’s overall growth. The Kanto region, home to major cities like Tokyo, leads the market due to its strong healthcare infrastructure, advanced research institutions, and high demand for medical innovations. Kansai follows with a solid industrial base and significant medical research contributions, particularly in orthopedics and dental applications. Chubu and Kyushu, while smaller in market share, are growing regions with increasing investments in biotechnology and medical device manufacturing. Leading players in Japan’s biomaterials market include Mitsubishi Chemical Corporation, Shinyei Kaisha, Terumo Corporation, Nippon Steel Corporation, and Kyocera Corporation. These companies are at the forefront of innovation, offering a wide range of biomaterials used across diverse applications such as orthopedics, cardiovascular, and tissue engineering. Their strategic R&D and product development efforts drive the market’s expansion.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Japan biomaterials market was valued at USD 12,074.40 million in 2024 and is projected to reach USD 38,281.73 million by 2032, growing at a CAGR of 15.52% during the forecast period (2024-2032).

The global biomaterials market was valued at USD 2,03,827.80 million in 2024 and is projected to reach USD 6,19,828.57 million by 2032, growing at a CAGR of 14.91% during the forecast period.
Market growth is driven by increasing demand for advanced medical devices, personalized medicine, and regenerative treatments.

The shift toward sustainable and biocompatible materials, such as biodegradable polymers and natural composites, is a significant trend in the market.
Competitive players like Mitsubishi Chemical Corporation, Terumo Corporation, and Kyocera Corporation dominate the market with strong R&D capabilities and diverse product portfolios.
High R&D costs and lengthy regulatory approval processes are key market restraints limiting the pace of innovation.
The Kanto region holds the largest market share, followed by Kansai, Chubu, and Kyushu regions, each contributing to regional market growth.
Japan’s strong focus on healthcare innovation and support for research facilitates further growth in the biomaterials market.

Report Scope

This report segments the Japan Biomaterials Market as follows:

Market Drivers

Aging Population and Growing Healthcare Needs

Japan has one of the world’s fastest-aging populations, with a significant increase in elderly citizens over the past few decades. By 2030, it is projected that nearly one-third of Japan’s population will be over the age of 65. For instance, reports from the World Economic Forum highlight that Japan consistently has the oldest population in the world, with more than 1 in 10 people aged 80 or older. This demographic shift presents a growing demand for medical solutions, including biomaterials used in orthopedic implants, prosthetics, and dental materials. Aging individuals often require medical interventions to maintain mobility and quality of life, driving the demand for advanced biomaterials that ensure compatibility, durability, and functionality. As a result, the biomaterials market is poised for sustained growth to meet the increasing healthcare needs of the aging population.

Advancements in Medical Technology and Research

Japan is at the forefront of medical technology and innovation, making substantial investments in research and development (R&D) to drive progress in the biomaterials field. This includes cutting-edge advancements in regenerative medicine, tissue engineering, and the development of more efficient biomaterials for medical applications. Japanese research institutions and companies are exploring novel materials such as biopolymers, ceramics, and biodegradable polymers, which offer enhanced biocompatibility and reduce the risk of complications. This ongoing innovation fosters the creation of next-generation biomaterials that meet the evolving requirements of modern healthcare, thereby fueling market expansion.

Government Support and Healthcare Policy Initiatives

The Japanese government plays a critical role in supporting the growth of the biomaterials market through policy initiatives and healthcare reforms aimed at enhancing medical treatment options and fostering technological innovation. For instance, the Japan External Trade Organization (JETRO) outlines government-backed programs promoting regenerative medicine and easing regulatory pathways for new biomaterials. Initiatives such as the promotion of regenerative medicine, the establishment of dedicated R&D funding, and the easing of regulatory pathways for new biomaterials have created a conducive environment for market development. Additionally, Japan’s focus on sustainability in healthcare products, coupled with policies encouraging the use of eco-friendly and biocompatible materials, is driving the demand for biomaterials that align with environmental and health-conscious standards. This support accelerates the development and adoption of new materials in the medical sector.

Rising Demand for Sustainable and Biocompatible Materials

There is an increasing demand for sustainable and biocompatible materials in the healthcare industry, driven by both consumer preferences and environmental concerns. Patients and healthcare providers are seeking materials that are not only effective but also reduce environmental impact. Biomaterials such as biodegradable polymers and eco-friendly composites have gained traction in Japan due to their minimal environmental footprint and suitability for long-term implantation in the human body. The shift toward these sustainable materials is supported by growing awareness of the environmental consequences of traditional medical products and the desire for materials that promote both health and environmental sustainability. As a result, the adoption of sustainable biomaterials is driving the market’s expansion while encouraging the development of novel solutions that align with both medical and ecological needs.

Market Trends

Surge in Personalized and Regenerative Medicine

Japan is making significant strides in personalized and regenerative medicine, driven by the country’s advanced technological landscape and commitment to innovation in healthcare. For instance, the Pharmaceuticals and Medical Devices Agency (PMDA) has introduced regulatory frameworks to support regenerative medicine, ensuring the safety and efficacy of stem cell-based therapies. The integration of cutting-edge technologies, such as 3D bioprinting and stem cell-based therapies, is revolutionizing the biomaterials market. Personalized medicine is increasingly being applied to develop custom biomaterials tailored to individual patients’ needs, ensuring more effective and targeted treatments. Regenerative medicine, which focuses on repairing or replacing damaged tissues and organs, is also gaining traction. In this context, biomaterials are essential for creating scaffolds that support tissue regeneration and facilitate the healing process. With Japan’s investment in R&D and its leadership in stem cell research, the demand for advanced biomaterials used in regenerative treatments is expected to increase significantly. This trend is particularly relevant in areas such as orthopedics, dental implants, and tissue engineering, where the need for customized and biologically compatible materials is critical.

Emphasis on Sustainable and Biocompatible Materials

Sustainability and biocompatibility are two of the most important trends currently shaping the Japanese biomaterials market. For instance, Japan’s Statistics Bureau has reported an increase in government-backed initiatives promoting biodegradable and eco-friendly biomaterials. As environmental concerns continue to rise, there is a growing preference for biomaterials that are eco-friendly, biodegradable, and cause minimal harm to both the human body and the environment. Japan’s healthcare sector is actively seeking sustainable alternatives to conventional biomaterials, such as biodegradable polymers, natural composites, and biopolymers, which can be safely absorbed by the body over time. These materials are particularly important in medical applications like drug delivery systems, wound healing, and implants, where they offer the dual benefit of reducing environmental impact while improving patient outcomes. Furthermore, the Japanese government is promoting sustainability through policies that encourage the development of green materials and practices in the healthcare industry. This emphasis on sustainable biomaterials aligns with global trends in environmental consciousness, making Japan a key player in the growing market for eco-friendly healthcare solutions.

Advancements in Functional Composites

Japan’s biomaterials market is experiencing rapid growth in the development of functional composites, which combine two or more materials to create a product that offers superior performance compared to its individual components. These advanced composites are increasingly used in a wide range of medical applications, including implants, prosthetics, and medical devices. The key advantage of functional composites is their ability to combine the beneficial properties of different materials, such as strength, flexibility, and biocompatibility, to create more durable and efficient products. For instance, composites made from ceramics and polymers are being used in orthopedic implants due to their enhanced mechanical properties and reduced risk of rejection. Japan’s leading position in manufacturing and material science has enabled the country to develop some of the most advanced functional composites in the biomaterials sector. These innovations are expected to drive further market growth as demand for high-performance biomaterials increases, especially in critical areas like joint replacements and tissue engineering.

Regulatory Support and Policy Initiatives

Japan’s regulatory framework and government policies play a pivotal role in shaping the biomaterials market. The Japanese government, through agencies such as the Pharmaceuticals and Medical Devices Agency (PMDA), provides significant support for the development and approval of new biomaterials. The regulatory processes in Japan are designed to ensure that only the safest and most effective materials are used in medical applications. Additionally, the government has been increasingly focused on facilitating the commercialization of innovative biomaterials through research funding, subsidies, and the streamlining of approval procedures. This has created a favorable environment for both local and international companies to invest in Japan’s biomaterials market. The Japanese government’s emphasis on regenerative medicine, sustainability, and advanced manufacturing also helps promote the development of cutting-edge biomaterials. By fostering an ecosystem that encourages innovation and provides robust regulatory support, Japan is positioning itself as a global leader in the biomaterials sector.

Market Challenges Analysis

High Research and Development Costs

One of the significant challenges facing the Japan biomaterials market is the high cost of research and development (R&D). For instance, Japan’s total expenditure on R&D in fiscal year 2022 reached 20.70 trillion yen, marking the highest level ever recorded. Developing innovative biomaterials that meet the stringent medical standards for biocompatibility, durability, and performance requires substantial investment in R&D. This includes both the cost of raw materials and the sophisticated technology needed for testing and manufacturing. For smaller companies, the financial burden of R&D can be prohibitive, limiting their ability to bring new biomaterials to market. Additionally, the time required to develop and validate new biomaterials, especially those used in critical applications like implants or tissue engineering, further increases costs. As a result, while large corporations can absorb these costs, smaller startups and research institutions may struggle to compete, leading to a concentration of innovation in the hands of a few large players.

Regulatory Hurdles and Approval Delays

Regulatory challenges also present significant barriers to the growth of Japan’s biomaterials market. While Japan has a well-established regulatory framework for medical devices and materials, the approval process for new biomaterials can be lengthy and complex. The Pharmaceuticals and Medical Devices Agency (PMDA) and other regulatory bodies require extensive clinical data and testing to ensure the safety and effectiveness of biomaterials before they can be commercialized. This process can lead to delays, particularly for new or innovative materials that lack precedent in the market. Furthermore, the global nature of the biomaterials industry means that companies must navigate different regulatory standards in other countries, adding complexity and further slowing time-to-market. These regulatory hurdles can create uncertainty for companies looking to introduce novel biomaterials, as well as increase costs associated with compliance and testing, slowing overall market growth.

Market Opportunities

Japan’s biomaterials market presents significant growth opportunities driven by ongoing advancements in medical technology and the country’s aging population. With a rapidly growing elderly demographic, the demand for biocompatible materials used in orthopedic implants, prosthetics, and dental solutions is expected to rise substantially. As healthcare demands evolve, there is also increasing interest in personalized medicine, which requires tailor-made biomaterials that can offer improved outcomes for individual patients. This creates an opportunity for companies to innovate in the development of specialized biomaterials that meet the specific needs of patients, such as bioresorbable implants or customized scaffolds for tissue engineering. The Japanese government’s strong support for healthcare innovation and research also creates a favorable environment for market expansion, with numerous incentives for companies focused on developing cutting-edge biomaterials.

Another key opportunity lies in the growing trend toward sustainable and eco-friendly biomaterials. As environmental concerns rise globally, there is an increasing demand for materials that not only offer superior performance but also reduce environmental impact. Japan’s focus on sustainability presents a promising market for biodegradable polymers, natural composites, and other sustainable biomaterials that can be used across medical applications. Furthermore, advancements in nanotechnology and 3D printing are opening up new possibilities in the design of highly functional, patient-specific biomaterials. These technologies offer the potential for more precise and efficient medical treatments, fostering opportunities for innovation in drug delivery systems, tissue regeneration, and medical implants. As a result, Japan’s biomaterials market is poised for continued growth, with opportunities for both established players and new entrants to capitalize on the evolving demand for advanced, sustainable, and personalized medical solutions.

Market Segmentation Analysis:

By Product Type:

The Japan biomaterials market is segmented by product type into metallic, ceramic, polymer, natural, and others, each serving distinct applications. Metallic biomaterials, which include stainless steel, gold, magnesium, and silver, are widely used in orthopedic implants, dental devices, and cardiovascular applications due to their strength, durability, and corrosion resistance. Stainless steel remains the most common material, particularly in surgical tools and joint replacements. Ceramic biomaterials, such as aluminum oxide, calcium sulfate, and glass, are used for their biocompatibility and ability to mimic the properties of natural bone. These materials are primarily used in orthopedics and dental applications. Polymer-based biomaterials, including polymethylmethacrylate, polyethylene, polyester, and nylon, offer versatility and are commonly used in drug delivery systems, wound healing, and prosthetics. Natural biomaterials, such as hyaluronic acid, collagen, gelatin, and fibrin, are gaining popularity in tissue engineering and regenerative medicine due to their biological compatibility and ease of integration with the human body. The “others” category includes advanced materials that combine different properties for specific uses, catering to niche medical applications.

By Application:

The Japan biomaterials market also experiences diverse applications across various medical fields. Orthopedics is one of the largest segments, with biomaterials used in joint replacements, bone grafts, and fracture fixation. The increasing aging population in Japan contributes to growing demand in this area. Cardiovascular applications also represent a significant portion of the market, with materials such as stents, heart valves, and vascular grafts being commonly used. The plastic surgery segment is seeing increased utilization of biomaterials for reconstructive procedures, skin grafts, and facial implants. Ophthalmology applications, particularly intraocular lenses and contact lenses, are also driving growth. Additionally, the dental market is benefiting from advancements in dental implants, which rely on biomaterials for durability and biocompatibility. The neurology and tissue engineering segments are emerging rapidly, with biomaterials playing a critical role in nerve repair and regenerative treatments. These diverse applications underscore the growing scope and potential of the biomaterials market in Japan, as the need for advanced and specialized materials continues to rise.

Segments:

Based on Product Type:

Metallic
Stainless Steel
Gold
Magnesium
Silver
Others
Ceramic
Aluminum Oxide
Calcium Sulfate
Carbon
Glass
Others
Polymer
Polymethylmethacrylate
Polyethylene
Polyester
Nylon
Others
Natural
Hyaluronic Acid
Collagen
Gelatin
Fibrin and others
Others

Based on Application:

Cardiovascular
Orthopedics
Plastic Surgery
Ophthalmology
Dental
Neurology
Tissue Engineering
Others

Based on the Geography:

Kanto Region
Kansai Region
Chubu Region
Kyushu Region
Other Regions

Regional Analysis

Kanto region

The Kanto region, which includes major cities like Tokyo and Yokohama, holds the largest market share in Japan’s biomaterials industry, accounting for approximately 40% of the total market. This dominance is driven by the region’s robust healthcare infrastructure, strong presence of leading medical institutions, and high demand for advanced medical technologies. The Kanto region is home to numerous biotechnology and pharmaceutical companies that are heavily involved in the research and development of biomaterials, particularly in the fields of orthopedics, cardiovascular, and regenerative medicine. The proximity to major research hubs and innovation centers, such as universities and hospitals, further contributes to the growth of the biomaterials market in this region.

Kansai region

The Kansai region, including Osaka, Kyoto, and Kobe, holds the second-largest market share, contributing around 30% to Japan’s total biomaterials market. This region is known for its strong manufacturing base, which plays a crucial role in the production and supply of biomaterials. Kansai is also a hub for advanced medical research, with several universities and research institutions focusing on biomaterial innovations, particularly in areas like tissue engineering, dental implants, and polymers. The region’s established medical device sector, along with the ongoing efforts to integrate sustainable biomaterials, further boosts market growth, particularly in the orthopedic and plastic surgery segments.

Chubu region

The Chubu region, comprising cities like Nagoya, contributes approximately 15% to the biomaterials market. Known for its industrial expertise and manufacturing prowess, Chubu plays a significant role in the production of high-performance biomaterials used in surgical instruments and medical devices. The region is also focusing on advancements in the field of nanotechnology and regenerative medicine, which are expected to drive future market growth. While the Chubu region is not as dominant as Kanto and Kansai, it is steadily gaining traction due to its increasing emphasis on medical research and development, especially in biotechnology.

Kyushu region

The Kyushu region, which includes Fukuoka and other southern cities, accounts for around 10% of Japan’s biomaterials market. While it has a smaller share compared to the other regions, Kyushu is emerging as a key player in the biomaterials sector. The region benefits from its growing focus on healthcare innovation, particularly in areas like neurology, ophthalmology, and tissue engineering. Additionally, Kyushu’s proximity to international markets in Asia makes it an important strategic location for companies looking to expand their biomaterials offerings in the region. With increasing investments in healthcare infrastructure and medical research, Kyushu’s market share is expected to grow steadily in the coming years.

Key Player Analysis

Mitsubishi Chemical Corporation
Shinyei Kaisha
Terumo Corporation
Nippon Steel Corporation
Kyocera Corporation

Competitive Analysis

The Japan biomaterials market is highly competitive, with several major players driving innovation and market growth. Leading companies include Mitsubishi Chemical Corporation, Shinyei Kaisha, Terumo Corporation, Nippon Steel Corporation, and Kyocera Corporation. These companies are at the forefront of developing advanced biomaterials and are heavily invested in research and development to maintain a competitive edge. Companies in this market are continuously focused on advancing their product portfolios, with an emphasis on cutting-edge technologies in materials science. Firms are particularly investing in R&D to develop new biomaterials that meet the evolving needs of the healthcare sector, including regenerative medicine, orthopedic implants, and drug delivery systems. The competition is driven by factors such as product quality, technological advancements, and the ability to meet stringent regulatory standards. Companies also compete by diversifying their offerings into specialized applications, such as personalized medicine and bio-based materials that promote sustainability. Strategic partnerships with research institutions and universities help strengthen innovation pipelines, while expanding geographic reach through strategic expansions in key markets is another competitive strategy. The market remains dynamic as businesses push the boundaries of traditional biomaterials to incorporate advanced composites, biodegradable materials, and nanotechnology. In this rapidly growing sector, staying ahead in terms of technological development and regulatory compliance is crucial for maintaining a competitive edge.

Recent Developments

In April 2025, BASF expanded its EcoBalanced portfolio for Care Chemicals in North America, introducing the first EcoBalanced personal care products in the region. These include Dehyton® PK 45 and Dehyton® KE UP, both certified as EcoBalanced grades using a biomass balance (BMB) approach to reduce carbon footprint. Additionally, six U.S. Care Chemicals production sites are now powered entirely by renewable electricity, saving approximately 33,000 tons of CO₂ annually.
In November 2024, Covestro began production of Desmophen® CQ NH, a partially bio-based polyaspartic resin (at least 25% bio-based content), at its Foshan, China site. The facility is powered entirely by renewable energy, and the product is used in wind turbine and flooring coatings, supporting both local supply and sustainability goals.
In January 2025, BASF’s Performance Materials division transitioned all European sites to 100% renewable electricity, covering engineering plastics, polyurethanes, thermoplastic polyurethanes, and specialty polymers.
In June 2023, Invibio announced a collaboration with Paragon Medical to scale up manufacturing of PEEK-OPTIMA Ultra-Reinforced composite trauma devices in China, responding to growing global demand for high-performance biomaterials in trauma fixation.
In February 2023, Celanese introduced ECO-B, more sustainable versions of Acetyl Chain materials, incorporating mass balance bio-content to provide chemically identical, bio-based alternatives for engineered materials.

Market Concentration & Characteristics

The Japan biomaterials market exhibits moderate to high concentration, with a few key players dominating the landscape while smaller companies contribute to specialized segments. The market is characterized by strong competition, particularly in the fields of orthopedic implants, cardiovascular devices, and regenerative medicine, where innovation and product differentiation are critical. Large companies with extensive R&D capabilities and global reach have a significant market share, while smaller firms focus on niche applications or emerging technologies, such as biodegradable materials and advanced composites. Companies often collaborate with research institutions and universities to foster innovation and maintain a competitive edge. The market is also highly influenced by regulatory standards, as companies must comply with stringent safety and performance requirements. The increasing demand for personalized and sustainable biomaterials is driving companies to innovate and expand their product portfolios, fostering a competitive environment where both established and emerging players actively contribute to market growth.

Report Coverage

The research report offers an in-depth analysis based on Product Type, Application and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Japan biomaterials market is projected to experience robust growth, driven by advancements in regenerative medicine and tissue engineering.
Increasing prevalence of chronic diseases, such as osteoarthritis and cardiovascular conditions, is fueling demand for biomaterial-based medical solutions.
The aging population in Japan is contributing to a higher incidence of age-related health issues, further boosting the need for biomaterials.
Technological innovations, including 3D bioprinting and smart biomaterials, are enhancing the development of personalized medical treatments.
Government initiatives and funding support are accelerating research and development in the biomaterials sector.
Growing awareness of environmental sustainability is leading to a shift towards eco-friendly and biodegradable biomaterials.
Collaborations between academic institutions and biotech firms are fostering the creation of novel biomaterials with improved functionalities.
The expansion of the healthcare infrastructure in Japan is facilitating the adoption of advanced biomaterial-based medical devices.
Regulatory reforms are streamlining approval processes, enabling faster commercialization of new biomaterial products.
The biomaterials market is expected to witness increased investment, leading to a more competitive and innovative industry landscape.

CHAPTER NO. 1 : INTRODUCTION 18

1.1.1. Report Description 18

Purpose of the Report 18

USP & Key Offerings 18

1.1.2. Key Benefits for Stakeholders 18

1.1.3. Target Audience 19

1.1.4. Report Scope 19

CHAPTER NO. 2 : EXECUTIVE SUMMARY 20

2.1. Japan Biomaterials Market Snapshot 20

2.1.1. Japan Biomaterials Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : JAPAN BIOMATERIALS MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.2.1. Rising Demand for Advanced Healthcare Solutions 24

3.2.2. Technological Advancements in Biomaterials Research and Increased Adoption of Implantable Devices 25

3.3. Market Restraints 26

3.3.1. Limited Awareness of New Technologies and Limitations Regarding Approvals 26

3.4. Market Opportunities 27

3.4.1. Market Opportunity Analysis 27

3.5. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2024 29

4.1.1. Japan Biomaterials Market: Company Market Share, by Volume, 2024 29

4.1.2. Japan Biomaterials Market: Company Market Share, by Revenue, 2024 30

4.1.3. Japan Biomaterials Market: Top 6 Company Market Share, by Revenue, 2024 30

4.1.4. Japan Biomaterials Market: Top 3 Company Market Share, by Revenue, 2024 31

4.2. Japan Biomaterials Market Company Revenue Market Share, 2024 32

4.3. Company Assessment Metrics, 2024 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2024 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

Japan Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : JAPAN BIOMATERIALS MARKET – BY PRODUCT TYPE SEGMENT ANALYSIS 37

6.1. Japan Biomaterials Market Overview, by Product Type Segment 37

6.1.1. Japan Biomaterials Market Revenue Share, By Product Type, 2023 & 2032 38

6.1.2. Japan Biomaterials Market Attractiveness Analysis, By Product Type 39

6.1.3. Incremental Revenue Growth Opportunity, by Product Type, 2024 – 2032 39

6.1.4. Japan Biomaterials Market Revenue, By Product Type, 2018, 2023, 2027 & 2032 40

6.2. Metallic 41

6.3. Stainless Steel 42

6.4. Gold 43

6.5. Magnesium 44

6.6. Silver 45

6.7. Others 46

6.8. Ceramic 47

6.9. Aluminum Oxide 48

6.10. Calcium Sulfate 49

6.11. Carbon 50

6.12. Glass 51

6.13. Others 52

6.14. Polymer 53

6.15. Polymethylmethacrylate 54

6.16. Polyethylene 55

6.17. Polyester 56

6.18. Nylon 57

6.19. Others 58

6.20. Natural 59

6.21. Hyaluronic Acid 60

6.22. Collagen 61

6.23. Gelatin 62

6.24. Fibrin 63

6.25. Others 64

6.26. Others 65

CHAPTER NO. 7 : JAPAN BIOMATERIALS MARKET – BY APPLICATION SEGMENT ANALYSIS 66

7.1. Japan Biomaterials Market Overview, by Application Segment 66

7.1.1. Japan Biomaterials Market Revenue Share, By Application, 2023 & 2032 67

7.1.2. Japan Biomaterials Market Attractiveness Analysis, By Application 68

7.1.3. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 68

7.1.4. Japan Biomaterials Market Revenue, By Application, 2018, 2023, 2027 & 2032 69

7.2. Cardiovascular 70

7.3. Orthopedics 71

7.4. Plastic Surgery 72

7.5. Ophthalmology 73

7.6. Dental 74

7.7. Neurology 75

7.8. Tissue Engineering 76

7.9. Others 77

CHAPTER NO. 8 : JAPAN BIOMATERIALS MARKET – JAPAN ANALYSIS 78

8.1. Product Type 78

8.1.1. Japan Biomaterials Market Revenue, By Product Type, 2018 – 2023 (USD Million) 78

8.1.2. Japan Biomaterials Market Revenue, By Product Type, 2024 – 2032 (USD Million) 78

8.2. Application 79

8.2.1. Japan Biomaterials Market Revenue, By Application, 2018 – 2023 (USD Million) 79

8.2.2. Japan Biomaterials Market Revenue, By Application, 2024 – 2032 (USD Million) 79

CHAPTER NO. 9 : COMPANY PROFILES 80

9.1. Mitsubishi Chemical Corporation 80

9.1.1. Company Overview 80

9.1.2. Product Portfolio 80

9.1.3. Swot Analysis 80

9.1.4. Business Strategy 81

9.1.5. Financial Overview 81

9.2. Shinyei Kaisha 82

9.3. Terumo Corporation 82

9.4. Nippon Steel Corporation 82

9.5. Kyocera Corporation 82

9.6. Company 6 82

9.7. Company 7 82

9.8. Company 8 82

9.9. Company 9 82

9.10. Company 10 82

9.11. Company 11 82

9.12. Company 12 82

9.13. Company 13 82

9.14. Company 14 82

List of Figures

FIG NO. 1. Japan Biomaterials Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Japan Biomaterials Market 28

FIG NO. 3. Company Share Analysis, 2024 29

FIG NO. 4. Company Share Analysis, 2024 30

FIG NO. 5. Company Share Analysis, 2024 30

FIG NO. 6. Company Share Analysis, 2024 31

FIG NO. 7. Japan Biomaterials Market – Company Revenue Market Share, 2024 32

FIG NO. 8. Japan Biomaterials Market Revenue Share, By Product Type, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Product Type 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Product Type, 2024 – 2032 39

FIG NO. 11. Japan Biomaterials Market Revenue, By Product Type, 2018, 2023, 2027 & 2032 40

FIG NO. 12. Japan Biomaterials Market for Metallic, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. Japan Biomaterials Market for Stainless Steel, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. Japan Biomaterials Market for Gold, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. Japan Biomaterials Market for Magnesium, Revenue (USD Million) 2018 – 2032 44

FIG NO. 16. Japan Biomaterials Market for Cooling Silver, Revenue (USD Million) 2018 – 2032 45

FIG NO. 17. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 46

FIG NO. 18. Japan Biomaterials Market for Ceramic, Revenue (USD Million) 2018 – 2032 47

FIG NO. 19. Japan Biomaterials Market for Cooling Aluminum Oxide, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Japan Biomaterials Market for Calcium Sulfate, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. Japan Biomaterials Market for Carbon, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. Japan Biomaterials Market for Glass, Revenue (USD Million) 2018 – 2032 51

FIG NO. 23. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 52

FIG NO. 24. Japan Biomaterials Market for Polymer, Revenue (USD Million) 2018 – 2032 53

FIG NO. 25. Japan Biomaterials Market for Polymethylmethacrylate, Revenue (USD Million) 2018 – 2032 54

FIG NO. 26. Japan Biomaterials Market for Polyethylene, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. Japan Biomaterials Market for Polyester, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. Japan Biomaterials Market for Nylon, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 58

FIG NO. 30. Japan Biomaterials Market for Natural, Revenue (USD Million) 2018 – 2032 59

FIG NO. 31. Japan Biomaterials Market for Hyaluronic Acid, Revenue (USD Million) 2018 – 2032 60

FIG NO. 32. Japan Biomaterials Market for Collagen, Revenue (USD Million) 2018 – 2032 61

FIG NO. 33. Japan Biomaterials Market for Gelatin, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. Japan Biomaterials Market for Fibrin, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 64

FIG NO. 36. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 65

FIG NO. 37. Japan Biomaterials Market Revenue Share, By Application, 2023 & 2032 67

FIG NO. 38. Market Attractiveness Analysis, By Application 68

FIG NO. 39. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 68

FIG NO. 40. Japan Biomaterials Market Revenue, By Application, 2018, 2023, 2027 & 2032 69

FIG NO. 41. Japan Biomaterials Market for Cardiovascular, Revenue (USD Million) 2018 – 2032 70

FIG NO. 42. Japan Biomaterials Market for Orthopedics, Revenue (USD Million) 2018 – 2032 71

FIG NO. 43. Japan Biomaterials Market for Plastic Surgery, Revenue (USD Million) 2018 – 2032 72

FIG NO. 44. Japan Biomaterials Market for Ophthalmology, Revenue (USD Million) 2018 – 2032 73

FIG NO. 45. Japan Biomaterials Market for Dental, Revenue (USD Million) 2018 – 2032 74

FIG NO. 46. Japan Biomaterials Market for Neurology, Revenue (USD Million) 2018 – 2032 75

FIG NO. 47. Japan Biomaterials Market for Tissue Engineering, Revenue (USD Million) 2018 – 2032 76

FIG NO. 48. Japan Biomaterials Market for Others, Revenue (USD Million) 2018 – 2032 77

List of Tables

TABLE NO. 1. : Japan Biomaterials Market: Snapshot 20

TABLE NO. 2. : Drivers for the Japan Biomaterials Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the Japan Biomaterials Market: Impact Analysis 26

TABLE NO. 4. : Japan Biomaterials Market Revenue, By Product Type, 2018 – 2023 (USD Million) 78

TABLE NO. 5. : Japan Biomaterials Market Revenue, By Product Type, 2024 – 2032 (USD Million) 78

TABLE NO. 6. : Japan Biomaterials Market Revenue, By Application, 2018 – 2023 (USD Million) 79

TABLE NO. 7. : Japan Biomaterials Market Revenue, By Application, 2024 – 2032 (USD Million) 79

Frequently Asked Questions

What is the current size of the Japan Biomaterials?

The Japan biomaterials market was valued at USD 12,074.40 million in 2024 and is projected to reach USD 38,281.73 million by 2032.

What factors are driving the growth of the Japan Biomaterials?

Key growth drivers include an aging population, rising demand for regenerative medicine, government support, and innovations in personalized and sustainable biomaterials.

What are some challenges faced by the Japan Biomaterials?

Challenges include high R&D costs, lengthy regulatory approval processes, and the need for compliance with strict safety standards.

Who are the major players in the Japan Biomaterials?

Major players include Mitsubishi Chemical Corporation, Shinyei Kaisha, Terumo Corporation, Nippon Steel Corporation, and Kyocera Corporation.

Purchase Options

Single User

$2699

Multi User

$3699

Custom Report

$5699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –